Acorda Therapeutics Inc., of Ardsley, N.Y., reported first quarter earnings, chalking up revenues from Ampyra (dalfampridine) of $72.5 million compared to $62.3 million for the same quarter in 2013. Zanaflex (tizanidine hydrochloride) capsules, tablets and authorized generic capsules generated revenues of $3.1 million compared to $4.4 million for the same quarter in 2013. Fampyra (prolonged-release fampridine) garnered royalties from sales outside of the U.S. of $2.4 million, compared to $2.9 million for the same quarter in 2013. Royalties in 2013 included a favorable adjustment of $1 million from the establishment of pricing in Germany, said Acorda, which ended the quarter with cash, cash equivalents and investments of $372.2 million and reiterated its full-year 2014 guidance regarding Ampyra net revenues, expected to bring in $328 million to $335 million. Shares of Acorda (NASDAQ:ACOR) closed Tuesday at $31.8, up 14 cents.

Vivus Inc., of Mountain View, Calif., disclosed total revenue for the first quarter of $36.7 million for the first quarter of 2014, compared to $4.1 million for the first quarter of 2013. Of the total, net product revenue was $9.1 million from sales of obesity drug Qsymia (phentermine/topiramate), compared to $4.1 million for the first quarter of 2013. The company recognized $19.4 million in license and milestone revenue, $7.4 million in supply revenue and $0.8 million in royalty revenue for the current quarter under its commercialization agreements for Stendra and Spedra, both brand names for avanafil. Though Wall Street was pleased overall, Credit Suisse analyst Lee Kalowski wrote in a research report that Vivus "needs to demonstrate that it can grow the market for Qsymia." Vivus ended the quarter with about $316.2 million on its balance sheet. The company's stock (NASDAQ:VVUS) closed Tuesday at $5.57, up 38 cents.